Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Debt: 2015-2023

Historic Non-Current Debt for Cartesian Therapeutics (RNAC) over the last 5 years, with Jun 2023 value amounting to $13.8 million.

  • Cartesian Therapeutics' Non-Current Debt fell 39.09% to $13.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was $13.8 million, marking a year-over-year decrease of 39.09%. This contributed to the annual value of $17.8 million for FY2022, which is 9.59% down from last year.
  • As of Q2 2023, Cartesian Therapeutics' Non-Current Debt stood at $13.8 million, which was down 15.04% from $16.2 million recorded in Q1 2023.
  • Cartesian Therapeutics' Non-Current Debt's 5-year high stood at $25.0 million during Q1 2022, with a 5-year trough of $6.4 million in Q2 2020.
  • For the 3-year period, Cartesian Therapeutics' Non-Current Debt averaged around $20.4 million, with its median value being $20.8 million (2021).
  • Its Non-Current Debt has fluctuated over the past 5 years, first spiked by 255.57% in 2021, then tumbled by 39.09% in 2023.
  • Quarterly analysis of 4 years shows Cartesian Therapeutics' Non-Current Debt stood at $24.8 million in 2020, then decreased by 20.65% to $19.7 million in 2021, then declined by 9.59% to $17.8 million in 2022, then crashed by 39.09% to $13.8 million in 2023.
  • Its last three reported values are $13.8 million in Q2 2023, $16.2 million for Q1 2023, and $17.8 million during Q4 2022.